Search

Displaying results 5421 - 5430 of 10000 in total
  1. Drug

    Elvucitabine

    go.drugbank.com/drugs/DB06236
    Investigational

  2. Drug

    Metenolone

    go.drugbank.com/drugs/DB13710
    Investigational

    Categories: Anabolic Agents for Systemic Use
  3. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels … Linifanib is intended for the treatment of hematologic malignancies and the solid tumors.

  4. Drug

    Torcetrapib

    go.drugbank.com/drugs/DB06281
    Investigational

    Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination of atorvastatin and the s...

  5. Drug

    Cariporide

    go.drugbank.com/drugs/DB06468
    Experimental

  6. Drug

    TG-C

    go.drugbank.com/drugs/DB06004
    Investigational

  7. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. … Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO.

  8. Drug

    Saredutant

    go.drugbank.com/drugs/DB06660
    Investigational

    Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

  9. Drug

    VLTS-589

    go.drugbank.com/drugs/DB05430
    Investigational

    VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.

  10. Drug

    AIT-034

    go.drugbank.com/drugs/DB06106
    Experimental

    There is some evidence that AIT-034 could complement Neotrofin as a treatment for Alzheimer's disease and dementia. … AIT-034 does not induce the production of NGF, and its mechanism of action is therefore believed to be different than Neotrofin.